Karyotype is an important prognostic factor in patients with newly diagnosed acute myeloblastic leukaemia (AML). The prognostic value of cytogenetics on the outcome of patients with AML in relapse has not yet been well defined. We analysed the clinical outcome of 152 patients with de novo, chemotherapy-treated AML in first relapse according to the cytogenetic classification of the United Kingdom Medical Research Council. The rate of second complete remission (CR) (88, 64 and 36%) and the probability of survival at 3 years (43, 18 and 0%) were significantly different between the favourable, intermediate and adverse cytogenetic risk groups, respectively. Compared to the favourable group, the relative risk (RR) of death (multivariate analyses) was 2.6 (confidence interval (CI): 1.5-4.4, Po0.001) for the intermediate and 3.7 (CI: 1.7-7.9, P ¼ 0.001) for the adverse group. The prognostic value of the duration of first CR was confirmed (RR of death: 2.0 (CI: 1.0-4.0) for each additional year in first CR), whereas the FLT3 mutation obtained at diagnosis did not markedly influence the outcome of patients with AML in relapse. In conclusion, our results indicate that both karyotype and the duration of first CR are independent prognostic factors for patients with de novo AML in first relapse.
Introduction
With modern chemotherapy, a haematological remission is achieved in 50-80% of patients with newly diagnosed de novo acute myeloblastic leukaemia (AML), but despite consolidation treatment the majority of patients will eventually relapse. [1] [2] [3] [4] Several pretreatment factors such as age, performance status, leucocyte count and karyotype predict the outcome, but karyotype is certainly the most important prognostic factor for the rate of complete remission (CR), overall survival (OS) and disease-free survival (DFS). [5] [6] [7] [8] [9] [10] [11] [12] Four large studies (and several smaller ones) demonstrated that the estimated OS at 5 years is around 35-65% among patients with favourable cytogenetics, while it is between 15 and 40% among patients with intermediate and below 20% among patients with adverse cytogenetics. [13] [14] [15] [16] The prognosis of patients after a first relapse of AML is generally poor. [17] [18] [19] [20] It has been shown that both the chance to achieve a second CR and the long-term outcome strongly depend on the duration of first remission. [21] [22] [23] [24] Kantarjian et al 25 were the first to address the issue of the prognostic value of cytogenetics in patients with AML in relapse. They reported that a favourable karyotype was more frequent in patients whose first remissions were at least 12 months, while the opposite was found in patients with an unfavourable karyotype. In 1989, Keating et al 22 reported that the karyotype was only predictive for patients with inv (16) or t1 (5, 17) with a relapse within 12 months after first CR. We have previously reported that the proportion of patients with a favourable karyotype is high among patients with a duration of second CR of more than 2 years. 26 Kern et al 27 found that unfavourable cytogenetics were associated with a lower rate of second CR and was a poor prognostic factor with regard to survival after first relapse. In the above-mentioned studies, a validated prognostic classification of cytogenetics (like the classification according to the United Kingdom Medical Research Council (MRC)) was not yet available and clear data on OS and DFS according to the cytogenetic risk categories were not provided. In 1998, Webb et al 28 investigated the outcome of 125 children with relapsed AML according to cytogenetics. The length of first remission and cytogenetics were highly correlated and in a univariate analysis both were prognostic factors. However, in a bivariate analysis the duration of first CR was of greater significance. Most recently, again, Kern et al 29 were able to show that the outcome of patients with relapsed AML was clearly dependent on the karyotype obtained at diagnosis. The likelihood of a second CR was 80, 49 and 30% in the favourable, intermediate and unfavourable cytogenetic risk groups. Moreover, the patients belonging to the unfavourable cytogenetic risk category had an inferior OS and event-free survival compared to the combined group of patients with intermediate or favourable cytogenetics. In their study, the interaction between cytogenetics and the duration of first CR has not been addressed.
In our leukaemia centre, we followed 152 consecutive adults with a first relapse of de novo, chemotherapy-treated AML, in whom cytogenetic data (confirmed by molecular data in the majority of cases) were available and investigated the impact of cytogenetics on the course of the disease after relapse. We also studied the interaction between karyotype and the duration of first CR and evaluated the impact of the FLT-3 mutation (FLT3/ ITD) on the outcome after relapse.
Patients and methods

Patients
Between January 1986 and June 2002, 536 consecutive patients with a diagnosis of de novo acute myeloid leukaemia were referred to our department. The complete diagnostic work-up, treatment and follow-up of these patients were performed in our centre. The diagnosis and morphological classification of AML were carried out as described previously. 26, 30, 31 Immunophenotyping and karyotyping were attempted in all patients, and molecular analysis in a large proportion of patients.
A flow chart of treatment strategies, treatment response and follow-up of the patients is given in Figure 1 . Of the 536 patients, 464 (87%) were treated with induction chemotherapy. In 93% of these patients, the induction treatment consisted of 45 mg/m 2 daunorubicin days 1-3 and 100-200 mg/m 2 cytarabine days 1-7. Of these, 260 (60%) patients additionally received etoposide (100 mg/m 2 for 5 days). Of 30 patients with acute promyelocytic leukaemia, 18 (60%) were treated with ATRA as part of induction therapy. Among the 464 patients, 310 (67%) achieved CR. A total of 35 patients (11.2%) were excluded from further analysis, since they underwent bone marrow transplantation (BMT) in first CR. Of the remaining 275 patients, 93% (n ¼ 255) received postremission therapy: 186 (73%) patients received consolidation therapy with intermediate-(1 g/m 2 ) or high-dose (3 g/m 2 ) cytarabine as a single agent or in combination with mitoxantrone or fludarabine. Another 62 (24%) patients were treated with consolidation chemotherapy similar to induction therapy (1 þ 7, 2 þ 5 or 3 þ 7). Four courses of consolidation therapy were aimed for the majority of patients, in particular, since the use of high-dose cytarabine. Five patients received a consolidation therapy according to the AIDAprotocol; the Bcr-Abl kinase inhibitor STI-571 was given to two patients with Philadelphia chromosome-positive AML.
In all, 14 patients (4.5%) were lost to follow-up in first CR, another 34 patients (11.0%) died in first CR. Of the remaining 227 patients with a first complete remission, 171 (75%) had a relapse during follow-up. Among these, cytogenetics were not available in 18 patients (10.5%). One patient was excluded from further analyses because he was lost to follow-up (allogeneic transplantation in early relapse outside the institute). The remaining 152 patients represent the study population for this analysis. In all, 40 (26%) patients with AML in first relapse were not treated; another four patients underwent successful allogeneic BMT (AlloBMT) in early relapse. The remaining 108 patients (71%) were treated by different salvage chemotherapy protocols:
. As a general rule, the initially applied induction therapy regimen was given again in patients with a long duration of first CR, while patients with a short first CR received chemotherapy consisting of high-dose cytarabine with mitoxantrone or fludarabine. Therefore, 52 of 68 patients (77%) with a duration of first CR shorter than 12 months received a salvage regimen, including high-dose cytarabine, in contrast to only 11 of 44 patients (25%) with a longer first CR. One patient refractory to two cycles of salvage chemotherapy (MIDAC, FLAG) underwent primarily successful AlloBMT without having achieved a second CR. Of the six patients with acute promyelocytic leukaemia in relapse, five (83%) had received ATRA as part of induction and of salvage chemotherapy. Among the 108 patients treated with salvage chemotherapy, 74 (69%) achieved a second CR. Among these, 16 (22%) patients underwent AlloBMT and seven (9%) patients autologous bone marrow transplantation in second CR. Of the remaining 51 patients, 30 (59%) received at least one cycle of the following consolidation chemotherapy regimens:
End points of the study
The end points of the study were the rate of second CR (%), OS, that is, time from start of salvage therapy to death, and DFS, that is, time from second CR to a second relapse or death. A CR was defined as 5% or less blast cells in a normocellular or hypercellular bone marrow with a normal peripheral and differential blood count.
Cytogenetic analyses and classification
Cytogenetic testing was performed from bone marrow obtained at diagnosis of AML prior to induction therapy. To investigate the impact of karyotype on the outcome in our study population, cytogenetics were categorised according to two independently established prognostic classifications: In the first place, the classification according to the United Kingdom MRC into three groups was applied; however, for comparison we also used the cytogenetic classification according to the criteria of the Southwest Oncology Study Group (SWOG) into four groups (of which three were prognostic): 13-15. According to the MRC criteria, favourable abnormalities included t(8;21), inv 16 and t(15;17) , irrespective of additional abnormalities. Among 24 of 35 patients with a favourable karyotype, molecular studies (AML1-ETO, CBFb-MYH11, PML-RARa) were performed and confirmed the cytogenetic result. Additional six patients with a normal karyotype were counted as favourable since molecular studies demonstrated the presence of AML1-ETO (n ¼ 2), PMLRARa (n ¼ 2) and CBFb-MYH11 (n ¼ 2). Cytogenetics were defined as adverse if they include at least five unrelated abnormalities (complex karyotype) or one of the following abnormalities (À5, del(5q), À7, abnormalities 3q). According to 
Figure 1
Diagram of treatment, response and follow-up in 536 patients with de novo AML. The study group consisted of 152 patients with AML in relapse, in which cytogenetics prior to induction treatment was available.
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A Weltermann et al the revised hierarchical risk group classification, the latter abnormalities in the adverse group were only counted in patients younger than 55 years of age. 15 Intermediate prognosis was assumed in the presence of either a normal karyotype or any other chromosomal change not encompassed by the favourable or adverse group. The classification according to the SWOG is somewhat different: Favourable abnormalities included t(8;21), inv 16 and t(15;17) , only the last two irrespective of additional abnormalities. Intermediate prognosis was assumed in the presence of either a normal karyotype or the detection of þ 8, þ 6, ÀY or del(12p). Cytogenetics were defined as adverse if they include one of the following abnormalities (À5, del(5q), À7, del(7q), abnormalities 3q, 9q, 11q, 20q, 21q or 17p, t(6;9) or t(9;22)) or at least three unrelated abnormalities (complex karyotype). All other chromosomal abnormalities not fulfilling the above-stated definitions of favourable, intermediate or adverse were grouped as an unknown prognostic value.
PCR analyses
Polymerase chain reaction (PCR) amplification of PML-RARa, AML1-ETO and CBFb-MYH11 was determined as reported previously. [32] [33] [34] To detect the FLT3/ITD mutation, exons 11 and 12 were amplified by single-step PCR from genomic DNA using the primers 11F, 5 0 -GCA ATT TAG GTA TGA AAG CCA GC-3 0 , and 12R, 5 0 -CTT TCA GCA TTT TGA CGG CAA CC-3 0 as described previously. 35, 36 PCR was performed using AmpliTaq DNA Polymerase (Perkin-Elmer Cetus, Norwalk, CT, USA) in a Perkin-Elmer GeneAmp PCR System 2400 thermocycler. The PCR mixture contained 500 ng of genomic DNA, 50 mM of MgSO 4 , 75 mM of MgCl 2 , 30 pM of each primer, 9.5 ml of 10 Â buffer, 94 mM of each deoxynucleotide triphosphate and 2 U of Taq polymerase (AmpliTaq, Perkin-Elmer, Norwalk, CT, USA). Denaturing, annealing and extension steps were performed at 941C for 30 s, 571C for 1 min and 721C for 2 min, respectively, for 35 cycles including an initial 3 min denaturation step at 941C and a final extension step at 721C for 10 min. PCR products (10 ml) were run on 2% agarose gel and visualised under UV light after ethidium bromide staining. The FLT3 wild type produced a band at 328 bp, whereas the FLT3/ITD produced additional bands at around 400 bp. A negative control consisting of the PCR mixture containing water instead of DNA was carried out with each PCR experiment.
Statistical analysis
Categorical data were compared between groups by means of contingency-table analyses (Fisher's exact test) and continuous data by means of Mann-Whitney U-tests and Kruskal-Wallis tests.
The dependence of the rate of second CR on age, gender, leucocyte count at diagnosis, the treatment period (three categories: 1986-1990, 1991-1995, 1996-2002) , the type of salvage therapy (three categories: chemotherapy regimens consisting of daunorubicin and low-dose cytarabine, chemotherapy regimens with high-dose cytarabine and all other chemotherapy regimens), cytogenetics and the duration of first CR was analysed by univariate and multivariate logistic regressions models. In contrast to the other covariables, the impact of the type of salvage treatment on the rate of second CR was studied a priori with adjustment for the duration of first CR, since the duration of first CR exercised an influence on the type of salvage treatment, that is, a short duration of first CR was related to chemotherapy regimens including high-dose cytarabine.
In the multivariate case, cytogenetics and the duration of first CR were included a priori in the model, while the other covariables were offered to a stepwise selection procedure. In addition, the duration of first CR was tested for possible nonlinear effects by adding cubic and quadratic terms, and for a possible interaction with cytogenetics in a stepwise selection procedure.
OS and DFS were analysed by means of Kaplan-Meier survival curve estimates and log-rank tests for group comparisons. 37 Three-year survival probabilities were also estimated after excluding patients undergoing AlloBMT in nonsecond CR and censoring patients undergoing BMT in second CR at the time of transplantation. Univariate and multivariate Cox's proportional-hazards models were used to analyse the influence of age, gender, leucocyte count at diagnosis, the treatment period, the type of salvage, cytogenetics, the duration of first CR and BMT (using a time-dependent covariable calculating the time from second CR to BMT). For patients undergoing BMT in early relapse, the time-dependent covariable was set to zero. As in the logistic regression model, only cytogenetics and the duration of first CR were included a priori in each multivariate model, while the other covariables were offered to a stepwise selection procedure. Again, the duration of first CR was tested for possible non-inear effects by adding cubic and quadratic terms. Furthermore, a stepwise selection procedure was performed for the following two purposes: first, for testing for a possible interaction of cytogenetics with the duration of first CR. Second, in order to test for potential nonproportionality of the hazards with respect to cytogenetics and the duration of first CR, terms have been added for the interaction between each of these variables and the logarithm of survival time. 38 In an additional analysis, the prognostic value of FLT3 on second CR and OS was investigated in univariate logistic and Cox's models, respectively, and included as a third a priori factor in the multivariate models, whereas an interaction term accounting for a possibly different influence of FLT3 in different MRC groups was added to the list of covariables offered to the stepwise selection procedure. P-values p0.05 were considered to be statistically significant; 95% confidence intervals (CIs) are given. All computations were performed using SPSS software Version 10.0 (SPSS Inc. Headquarters, Chicago, IL, USA) and SAS software Version 8.2 (SAS Institute Inc., Cary, NC, USA, 2001).
Results
Patient characteristics
A detailed list of the cytogenetic findings (according to the MRC classification) of relapsed patients is given in Table 1 . Favourable, intermediate and adverse cytogenetics were observed in 23% (n ¼ 35), 67% (n ¼ 102) and 10% (n ¼ 15), respectively. The baseline characteristics at diagnosis of the 152 patients are given in Table 2 . Patients with favourable cytogenetics were significantly younger than patients with an intermediate or an adverse karyotype. The duration of first CR was shorter among patients with adverse cytogenetics (6.6 months) than among patients with an intermediate karyotype (8.9 months, P ¼ 0.071) or with a favourable karyotype (10.6 months, P ¼ 0.031), respectively. The rate of patients receiving salvage chemotherapy was highest in the favourable group (97% as compared to 66% in the intermediate and 73% in the adverse group). Compared to patients with salvage treatment, patients who did not receive salvage therapy at first relapse (n ¼ 40) featured adverse prognostic factors. These patients were significantly older (67716 vs 52716 years, Po0.001), the duration between first induction therapy and first CR was significantly longer (60731 vs 46727 days, P ¼ 0.01) and the duration of first CR was significantly shorter (7.676.3 vs 13.3710.9 months, Po0.001).
The overall CR rate among patients treated with salvage chemotherapy (n ¼ 108) was 69% (CI: 60-77%). The low death rate was worth noting during salvage therapy, which can be explained by the good performance status of most patients and the exclusion of high-risk patients (Table 2 ). All patients undergoing AlloBMT in early first relapse (n ¼ 4) achieved CR. After a second CR, nine (31%) patients with favourable cytogenetics underwent AlloBMT, as compared to seven (17%) patients with intermediate cytogenetics, respectively.
Impact of cytogenetics, duration of first CR and various pretreatment variables on the rate of second CR Among patients undergoing salvage chemotherapy, the probability of a second CR was (significantly) higher in the favourable group (88%) than in the intermediate (64%) and Cytogenetics (determined at diagnosis) were categorised according to the criteria of the United Kingdom MRC into three groups. a Percentage among cytogenetic groups with a frequency below n ¼ 3 is not given.
b X5 unrelated abnormalities. One patient -refractory to two cycles of salvage chemotherapy -underwent allogeneic SCT. c Percentage of patients with second CR after salvage chemotherapy.
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A Weltermann et al adverse group (36%) ( Tables 2 and 3 ). Applying a logistic regression model, the odds to achieve a second CR was 0. The duration of first CR was a further significant prognostic factor for treatment response. The odds of a second CR increased by 2.0 (CI: 1.0-4.0, P ¼ 0.04) for each additional year in first CR. In contrast, various pretreatment variables obtained at diagnosis (age, gender, leucocyte count) and treatment variables (treatment period, type of salvage therapy (adjusted for the duration of first CR)) had no significance in the respective univariate logistic regression models.
In a multivariate regression model, applying adjustment for the duration of first remission and stepwise adjustment for age, gender, leucocyte count, the treatment period and the type of salvage therapy, the impact of both cytogenetics and the duration of first CR on the CR rate remained almost unchanged 
Impact of cytogenetics on OS and DFS
From the date of relapse, the probabilities of survival at 3 years in the 152 patients were 42% (CI: 25-59%) in the favourable, 12% (CI: 5-19%) in the intermediate and 0% in the adverse cytogenetic group. The OS of the 40 patients who did not receive salvage chemotherapy was only 8% (CI: 3-12%) at 1 year. None of these patients survived beyond 2 years from relapse. Among the 108 patients receiving salvage chemotherapy, patients belonging to the favourable risk category had a superior survival, as compared to patients in the intermediate and the adverse group, respectively ( Figure 2 , Table 3 ). At 3 years, the probabilities of survival were 43% in the favourable and 18% in the intermediate group, while none of the 11 patients with adverse cytogenetics survived beyond 3 years, indicating the highly negative predictive value of an unfavourable karyotype. The difference between the favourable and intermediate groups remained quite similar, if the data of patients undergoing BMT were censored at the time of transplantation: 37% OS (CI: 16-60%) in the favourable and 17% OS (CI: 6-28%) in the intermediate group.
Compared to the favourable group, the estimated relative risk (RR) of death was 2.5 for the intermediate group and 4.7 for the adverse group (Table 3) . After adjustment for the duration of first CR and stepwise adjustment for age, gender, leucocyte count, the period of treatment, the type of salvage therapy and BMT, the estimated RRs remained quite similar (intermediate group: RR 2.6, Po0.001; adverse group: RR 3.7, P ¼ 0.001). Among the stepwise selected covariables, only BMT entered the model since it exercised a significant influence on the OS (RR 0.52, CI: 0.27-0.98, P ¼ 0.044).
The probability of DFS after second CR also varied significantly according to the cytogenetic risk category (Figure 3, Table 3 ). At 3 years, the probability of DFS was 26% in the favourable and 17% in the intermediate cytogenetic group. None of the patients in the adverse group achieved a DFS for more than 3 years. Compared with the favourable group, the estimated RR of death or relapse from second CR was 1.6 for the intermediate group and 4.2 for the adverse group, which remained almost unchanged after multivariate adjustment (Table 3) . Among the stepwise selected covariables, BMT (RR 0.26, CI: 0.11-0.61, P ¼ 0.002) and age (RR 0.975, CI: 0.952-0.999 for each year increase, P ¼ 0.039) had a significant influence on the OS. OS of patients with de novo AML in relapse undergoing salvage therapy (n ¼ 112) according to the karyotype. Cytogenetics were categorised according to the criteria of the United Kingdom MRC. The P-value shown has been pooled over strata (log-rank test).
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Comparison of the outcome according to the classifications of MRC and SWOG
Owing to a similar definition of the favourable risk group, only one of 35 patients categorised as favourable in the MRC classification has been shifted to another risk group in the SWOG classification. Thus, the outcome of patients belonging to the favourable risk group was almost identical between both classifications (Tables 3 and 4) . In contrast, the number of patients in the intermediate-risk group in both classifications was different (SWOG: n ¼ 42, MRC: n ¼ 67), because patients with infrequent aberrations were mainly grouped as cytogenetics of unknown prognostic significance in the SWOG classification. Nevertheless, the outcome of patients with intermediate cytogenetics was only marginally different between both classifications, with a slightly better outcome in the SWOG classification (Tables 3 and 4) . The different definitions of adverse cytogenetics resulted in a higher number of patients belonging to the adverse risk group in the SWOG classification (SWOG: n ¼ 26, MRC: n ¼ 11). For instance, in the MRC classification, cytogenetics were defined as adverse if they include at least five unrelated abnormalities, while in the SWOG classification already three unrelated abnormalities resulted in an assignment into the adverse group. It was therefore of no surprise that the rate of a second CR was lower in the MRC classification (Tables 3 and 4) . However, the longterm outcome (OS, DFS) was extremely poor using both classifications (Tables 3 and 4) .
Interaction of cytogenetics and the duration of the first CR on the outcome of AML in relapse
In our patient cohort, the duration of a first CR was a strong predictor for the outcome. The odds ratio for the probability to achieve a second CR was 2.0 (CI: 1.0-4.0, P ¼ 0.04) for each additional year in first CR. Moreover, there was an inverse relation between the duration of a first CR and the risk of death (RR 0.55, CI: 0.40-0.77 for each additional year in first CR, Po0.001).
As has already been mentioned, multivariate adjustment did not affect the odds or hazard ratios, respectively, of both cytogenetics and the duration of first CR with regard to the outcome measures (second CR, OS, DFS) to a significant degree. With regard to the rate of second CR and DFS, there was moreover no significant interaction between cytogenetics and the duration of first CR detectable. However, we detected a significant interaction between cytogenetics and the duration of first CR for OS (P ¼ 0.015). This means that the RRs in the intermediate and the adverse group, respectively, relative to the favourable group depend on the duration of first CR: In the intermediate cytogenetic risk group, the RRs amounted to 2.2 (CI: 1.0-4.6), 2.7 (CI: 1.5-4.9) and 4.4 (CI: 1.3-14.7) for patients with a duration of first CR of half a year, 1 year and 2 years, respectively. In the adverse cytogenetic risk group, the RRs were 8.2 (CI: 2.9-23.2) and 2.0 (CI: 0.7-5.9) for patients with a duration of first CR of half a year and 1 year, respectively, whereas there was no patient in the adverse group with a duration of first CR of 2 years.
To study the interaction between both risk factors graphically, we stratified these patients into four groups. Owing to the extremely poor outcome in patients with unfavourable cytogenetics independent of the duration of first CR (Table 3 DFS of patients with de novo AML in second CR (n ¼ 79) according to cytogenetics. Cytogenetics were categorised according to the criteria of the United Kingdom MRC. The P-value shown has been pooled over strata (log-rank test). Reference group. c Data were adjusted for the duration of first CR and (stepwise selection) for gender, age, period of treatment, type of salvage therapy and BMT. d DFS and RR of relapse or death from second CR. Data of patients (n ¼ 11) with cytogenetics of unknown prognostic significance are not given.
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A Weltermann et al and intermediate cytogenetics (28%) had a better OS after relapse, but the difference reached only marginal statistical significance due to the rather low number of patients in each group (P ¼ 0.03 and 0.02, respectively, compared to patients with a short duration of first CR and intermediate cytogenetics). The OS was best among patients with both favourable cytogenetics and a long duration of first CR (estimate of OS at 3 years: 66%, Pp0.001) compared to patients with a short duration of first CR and intermediate cytogenetics.
Prognostic value of the FLT-3 mutation on the outcome of AML in relapse DNA from diagnosis for the determination of the internal tandem duplication of the FLT3 gene (FLT3/ITD) was available in 55 of 112 patients (49%) receiving reinduction therapy. The FLT3/ITD mutation was found in 29% of these patients (16 out of 55). Not unexpectedly, the percentage of patients with a long duration of first CR (412 months) was higher in the patients without FLT3/ITD (41 vs 19% months, P ¼ 0.13). After relapse, the likelihood of a second CR was comparable between patients with and without FLT3/ITD (67 vs 69% months, P ¼ 0.88). After a second CR, the probabilities of OS at 3 years were 12% (0-34%) and 43% (22-65%) in patients with and without FLT3/ITD (P ¼ 0.15), respectively. Compared to patients without FLT3/ ITD, the RR of death was 1.5 (0.8-3.0, P ¼ 0.23). After adjustment for the duration of first CR and stepwise adjustment for age, gender, leucocyte count, the period of treatment, the type of salvage therapy and BMT, an increased risk of death associated with the presence of FLT3/ITD was no longer detectable (RR 1.0, CI: 0.5-2.0, P ¼ 0.95). The loss of the relative effect of FLT3/ITD in the multivariate analysis did not differ between the cytogenetic risk groups, that is, the corresponding interaction was not significant.
Discussion
In newly diagnosed AML, the impact of cytogenetic abnormalities on the CR rate, OS and DFS has already been proven. For these patients, large studies defined three prognostic groups according to the karyotype. The prognostic impact of cytogenetics for the outcome in patients with a first relapse has already been investigated in several studies. The principal finding of our study was that the recently established classifications of both the United Kingdom MRC and the SWOG are also useful to predict the outcome of patients with a first relapse of de novo, chemotherapy-treated AML. The karyotype obtained at diagnosis and categorised according to either classification is an important independent prognostic factor for the achievement of a second CR, OS and DFS of patients with a first relapse. According to the MRC criteria, the CR rate of patients receiving salvage chemotherapy amounted to 88, 64 and 36% among patients with favourable, intermediate and adverse cytogenetics, respectively. Moreover, there was a clear stepwise better OS and DFS from the adverse to the favourable cytogenetic risk category.
In the present study, the proportion of patients receiving salvage chemotherapy decreased with a worsening risk category of cytogenetics. This was at least partially explained by the younger age in the favourable group, and may also reflect a general restraint to apply salvage chemotherapy to patients with a short duration of first remission and/or elderly patients, because of the expected higher rate of complications. Not surprisingly, the overall CR rate among our patients treated with salvage chemotherapy was high (69%), which was certainly also due to the exclusion of patients with secondary AML in our population. However, the long-term outcome (OS and DFS) of patients in relapse was much inferior as compared to patients with previously untreated AML. At 3 years, the probabilities of OS and DFS were only 24% (CI: 16-32%) and accordingly 18% (CI: 8-28%), which corresponds to data from the literature. 27, 29, 39, 40 In accordance with many previous studies, we confirmed that the duration of first CR is an important prognostic factor for the achievement of second CR, the duration of OS and DFS from second CR. [21] [22] [23] [24] There was a significant relation between the duration of first CR and the parameters of clinical outcome (rate of second CR, OS and DFS). Since the cytogenetic risk category may exert an influence on the effect of the duration of first remission on the outcome after relapse, we analysed the interaction of both parameters. In contrast to the rate of second CR and the DFS, the RR of death in the intermediate-risk group (as compared to the favourable group) increased with the duration of first CR. These data suggest that the prognostic impact of cytogenetics on OS was more pronounced in patients with a longer duration of first CR, as compared to patients with a shorter duration of first CR. The outcome of patients in the adverse risk group was still poor even in patients with a long duration of first CR, which is in agreement to the literature. 28 Thus, a further analysis in this study was restricted to the intermediate or favourable cytogenetic risk group, since these patients might have a change of cure. In a bivariate analysis (Cox's proportional-hazards model), both a duration of first remission shorter than 12 months (as compared to a first remission longer than 12 months) and an intermediate karyotype (as compared to favourable cytogenetics) were associated with an around two-fold higher RR of relapse. Moreover, there was an independent synergistic effect of karyotype and the duration of first CR, since patients with both a long first remission and a favourable karyotype had a better outcome than patients with only one or none of these conditions. This finding implies that besides the well-known prognostic value of the duration of a first CR, karyotype is another independent prognostic factor for patients with AML in first relapse. The difference of definitions of cytogenetic risk categories between the MRC and SWOG classifications resulted in an unequal grouping of patients, mainly in the intermediate and adverse group. Nevertheless, the outcome according to the cytogenetic risk categories was comparable between both classifications. For instance, even though the number of patients belonging to the adverse risk group of the SWOG classification was two-fold higher than in the MRC classification, the longterm outcome of these groups was similarly poor. These results might be explained by larger subgroups in the intermediate and unfavourable groups, respectively, which determine the overall outcome in these groups. For instance, the outcome in the intermediate group is dependent on the large proportion of patients with a normal karyotype. The inclusion of other subgroups in the intermediate group will thus have a marginal effect on the outcome. Similar effects might be present in the adverse group, in which the complex karyotype, often including abnormalities of chromosomes 5/7, determine the general poor outcome irrespective of the inclusion of other subgroups. The genuine prognostic impact of the cytogenetic abnormalities fluctuating between intermediate and poor (11q23, trisomy 8, other trisomies, etc) as well as that of the less common cytogenetic abnormalities will need larger series to be determined (perhaps an international series to obtain statistically analysable cohorts).
Cytogenetic analyses in our patients were performed at diagnosis of AML. It is known that patients at relapse may acquire additional cytogenetic abnormalities. Estey et al 41 found that a change in the cytogenetic pattern at first relapse does not influence the prognosis of therapy for first relapse in the great majority of patients. Data observed by Kern et al 29 suggest that cytogenetics at relapse tended to be related to the outcome more strongly than cytogenetics at diagnosis. We have not studied this question among our patient cohort systematically. Among the 25 patients with a karyotype obtained at diagnosis and at first relapse in our population, the likelihood of a cytogenetic finding at relapse belonging to the same risk category was approximately 70% (data not shown); the others had shifted to a worse risk category. The issue of whether or not cytogenetics obtained in relapse is more predictive could not be analysed in our study due to the low number of patients with both a karyotype obtained at diagnosis and at relapse.
For several reasons, we believe that these results are representative for patients with de novo, chemotherapy-treated AML in relapse. The number of patients lost to follow-up was low, since routinely all patients are in regular follow-up in our outpatient clinic. Furthermore, the performance of all laboratory examinations in one centre has the advantage of uniform diagnosis criteria. Cytogenetics were available in 90% of the patients and in many patients cytogenetics were complemented by FISH and molecular studies. It must be emphasised that our data are not the result of a randomised study. The treatment strategies changed during the observation time from 1986 until now, since during this time period the number of patients eligible for allogeneic, peripheral stem cell transplantation increased. Chemotherapy regimens for salvage chemotherapy remained essentially unchanged during the observation time, with the exception of G-CSF, which was used in many patients in the recent years. A large proportion of our patients had received high-dose cytarabine as part of consolidation therapy in first remission. Among the six patients with acute promyelocytic leukaemia in the study population, five had received ATRA as part of induction and salvage chemotherapy, indicating a truly good risk population. All bone marrow and stem cell transplantations were conducted in the same institution. Owing to these features, the result of this study may well reflect the results in daily practice, even though the heterogeneity of treatment due to the large study period is a limitation of our study.
In patients with de novo AML, the presence of FLT3/ITD is associated with an inferior outcome. 36, 42, 43 The prognostic impact of this mutation in patients with AML in relapse has not been investigated. In the present study, the impact of FLT3/ITD could be analysed in about 50% of the study population. The rate of second CR did not differ between patients with and without FLT3/ITD, but our data suggest an adverse OS from relapse in patients with FLT3/ITD. In the multivariate analysis, however, the prognostic impact of FLT3/ITD was no longer detectable. The loss of the relative effect of FLT3/ITD in the multivariate analysis was similar between the cytogenetic risk groups. Owing to the low number of patients available for this analysis, a slight effect of FLT3/ITD cannot be ruled out. However, our data suggest that FLT3/ITD obtained at diagnosis does not have an additional prognostic impact on the outcome of patients with de novo, chemotherapy-treated AML in first relapse. The loss of prognostic impact might be explained by a population bias. The proportion of patients without relapse is higher among patients without FLT3/ITD and those patients are not included in the present study. Therefore, the patients with relapse despite the absence of FLT3/ITD at diagnosis represent a primary adverse risk group. Moreover, recent data indicate a frequent loss of FLT3/ITD at relapse or new acquirement of FLT3/ITD at relapse. 44, 45 Thus, the impact of FLT3/ITD obtained at relapse might be more informative. Larger studies are needed to assess the role of this mutation in patients with AML in first relapse finally.
In conclusion, from our data, it appears that in patients with poor cytogenetics the chance of cure after relapse is almost zero with chemotherapy and very low even with allogeneic SCT. Among patients with favourable cytogenetics and, to a lesser extent, among patients with intermediate cytogenetics, there is a small chance of cure after the first relapse, which also depends on the duration of first CR and the availability of BMT in second CR. The FLT-3 mutation obtained at diagnosis did not significantly influence the outcome of patients after relapse.
